Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

The trial is funded through Abu Dhabi’s Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa affects an estimated 60,000 patients worldwide

Opus Genetics Launches First Clinical Trial for MERTK-Related RP Gene Therapy

Opus Genetics announced the launch and funding of a clinical trial evaluating its gene therapy for MERTK-related retinitis pigmentosa (RP), a rare inherited eye disease that causes progressive vision loss and eventual blindness. The clinical trial will evaluate the safety and efficacy of OPGx-MERTK, an investigational adeno-associated virus (AAV)-based gene therapy developed by Opus Genetics. The therapy is designed to deliver a functional copy …